Bristol Myers Stock Rises Amid Delays and Updates on Alzheimer’s Drug Trials
Bristol Myers Squibb's stock rose over 5% after delaying the results of a clinical trial for Cobenfy, a drug for Alzheimer's disease psychosis, due to enrollment irregularities. The delay, expected to extend the trial completion to 2026, suggests positive trends despite concerns, and the stock's movement reflects investor optimism about the potential market and ongoing development efforts.